Bowenoid Papulosis Treatments

Find Bowenoid Papulosis Treatments

Brand Name

Condylox

Generic Name

Podofilox

View Brand Information

FDA approval date: March 13, 1997

Form: Solution, Gel

What is Condylox (Podofilox)?

Condylox Gel 0.5% is indicated for the topical treatment of anogenital warts . This product is not indicated in the treatment of mucous membrane warts. Diagnosis Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma and "Bowenoid papulosis" is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with Condylox Gel 0.5.

Approved To Treat

Top Global Experts

Kang Zeng

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia

Who is this study for: Adult patients with diffuse large B-cell lymphoma and other lumphomas

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Procedure, Drug, Biological, Other, Dietary supplement

Study Drugs: Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Oxaliplatin, Rituximab

Study Phase: Phase 2

Summary: This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ...

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug

Study Phase: Phase 2

Background: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head. One drug (belinostat), combined with 2 other drugs (etoposide and cisplatin), is approved to treat HGNEC. But some people may have a gene variant that affects how quickly their body gets rid of the drug; these people may do better with diffe...

View All Clinical Trials

Related Latest Advances

Designer Podophyllotoxin Derivatives with Significantly Improved Safety by Targeting LAT1 for the Treatment of Esophageal Cancer.

Journal: Journal of medicinal chemistry

Published: April 14, 2026

Trophoblast aging driven by IL33 deficiency elevates recurrent pregnancy loss risk through SNAP29 lactylation-mediated autophagy impairment.

Journal: Autophagy

Published: April 14, 2026

Retained Unexploded Ordnance: A Safety Analysis of Diagnostic Ultrasound on Piezoelectric Fuzes.

Journal: Military medicine

Published: April 13, 2026

View All Latest Advances